Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- PET Imaging Agent Vizamyl Filed for Additional Use for AD Modifying Drug
April 13, 2023
- Alexion Japan Recalling Ultomiris IV 300 mg/3 mL
April 13, 2023
- Japan Lacks Talent, Ecosystem to Incubate Drug Seeds: Chugai Chair
April 13, 2023
- Astellas, Kyoto University’s CiRA Extend iPS Cell Pact
April 13, 2023
- Astellas Incurs 58 Billion Yen Impairment Loss on Sluggish Evrenzo, Other Factors
April 12, 2023
- Sumitomo’s SaMD for Depression Gets Priority Review; Clinical Trial Launch Eyed within 3 Years
April 12, 2023
- BA.4/5-Based Jab Filed for 6 Months to 4 Years in Japan: Pfizer/BioNTech
April 12, 2023
- Meiji/CSL Seqirus Tie Up for Sales of COVID-19 mRNA Vaccine in Japan
April 12, 2023
- Shionogi Seeks EUA for Xocova in Taiwan
April 12, 2023
- Novo Japan Sales Renew Record in 2022 as Ozempic, Rybelsus Blossom
April 12, 2023
- Wakamoto to Halt Shipments of MaQaid on Quality Issues
April 11, 2023
- Shionogi Begins Global PIIb Stroke Study for Regeneration-Inducing Medicine
April 11, 2023
- MSD Rolls Out 15-Valent Pneumococcal Vaccine Vaxneuvance in Japan
April 11, 2023
- Amgen Eyes Simultaneous Filing in Japan, US, EU for 3 Key Drivers, including Next-Gen BiTE Drug: R&D Chief
April 11, 2023
- Ono/BMS Settles PD-1/PD-L1 Patent Row with Dana-Farber
April 10, 2023
- Generic Shipment Price Rate Likely Rose 1.5% for FY2023 Revision, Weighing on Wholesalers
April 10, 2023
- Sanofi Discontinues Sales of Allegra Dry Syrup in Japan
April 10, 2023
- Insud’s Oral Contraceptive Filed in South Korea: ASKA
April 10, 2023
- Japan Ethical Drug Sales Up 0.6% in February: Crecon
April 10, 2023
- Lenvima/Keytruda Combo Fails in 1st-Line Melanoma Study
April 10, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…